阿尔茨海默症 z-bo 2020-09-19 387

　　In 2015, the Alzheimer's Association released a set of data: At present, there are 44 million Alzheimer's patients worldwide, and it is expected that this will rise to 135 million by 2050. This data is huge, and the cost of treatment behind the data may be overwhelming for ordinary families. Although the pathology and medical research of Alzheimer's disease has been studied for many years, the progress has been slow. There is currently no clear drug cure.

　　However, cell therapy experiments in animal models have found that human umbilical cord blood cells (HUCBCs) can improve some of the cognitive deficits of diseased mice and reduce the deposition of β-amyloid. This undoubtedly brought dawn to the study of Alzheimer's disease and provided new treatment ideas and directions.

　　Peripheral blood mononuclear cells clear β-amyloid protein and improve cognitive ability

　　β-amyloid, which is hydrolyzed by amyloid prerequisite protein (APP), accumulates in the brain and can cause toxic effects on the brain nerves. It is a typical indicator of Alzheimer's disease detection.

　　Research teams from the United States, China, and Japan have confirmed that peripheral blood mononuclear cells can effectively remove β-amyloid deposits in the brains of diseased mice. However, the mechanism of action of cord blood cells on β-amyloid is not yet known.

　　The author of the article, Donna Darlington, PhD in neurodevelopmental sciences in Rashid Lab at the University of South Florida, said: “We previously reported that HUCBCs can treat inflammation, clear beta-amyloid, and alleviate symptoms in Alzheimer’s mice. In this study, We are trying to figure out the mechanism by which peripheral blood mononuclear cells act on β-amyloid. "Related research results will soon be published in the journal Cell Transplantation.

　　Researchers used umbilical cord blood cells to treat Alzheimer's disease mice, and tracked and analyzed the behavioral characteristics, physiological and biochemical responses and histology of the mice after treatment. It took 2-4 months. The study found that peripheral blood mononuclear cells can not only eliminate the deposition of β-amyloid in the mouse brain, but also improve the learning, memory and motor skills in the hippocampus.

　　Peripheral blood mononuclear cells can eliminate dead cells and cell debris through phagocytosis

　　Researchers believe that phagocytosis may be the mechanism by which peripheral blood monocytes eliminate β-amyloid. Importantly, studies have found that the efficiency of senescent monocytes to clear β-amyloid is significantly reduced, and soluble amyloid precursor protein (sSPPa) can restore the phagocytic function of these endogenous senescent cells.

　　This research is of great significance for the analysis of the mechanism of monocyte treatment of Alzheimer's disease. The researchers said that in the future, they will focus on the benefits of using peripheral blood mononuclear cells for cell therapy, as well as possible side effects, such as the secretion of neurotoxins. Is it feasible to use peripheral blood mononuclear cells to treat patients with Alzheimer's disease? This is also verified by further research.